EcoDrugPlus

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSHHUG00000042052
Gene Symbol: NT5E
1 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSHHUG00000046016
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSHHUG00000001848
Gene Symbol: HTR2B
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSHHUG00000030221
Gene Symbol: HTR2B
2 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSHHUG00000014022
Gene Symbol: HTR2CL1
1 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSHHUG00000023975
Gene Symbol: HTR2CL1
1 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSHHUG00000025729
Gene Symbol: HTR1B
2 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSHHUG00000040987
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSHHUG00000042465
Gene Symbol: HTR1B
2 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSHHUG00000037600
Gene Symbol: HTR1E
2 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSHHUG00000041730
Gene Symbol: HTR1E
2 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSHHUG00000026109
Gene Symbol: HTR1E
2 Cross references
139 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).